Search

DIFFERENCES IN GENE SEQUENCING AND THE TUMOR MICROENVIRONMENT LEADING TO DISCORDANCE IN PATHOLOGIC TREATMENT EFFECT FOLLOWING IMMUNE CHECKPOINT INHIBITION (ICI) IN HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)

Immunotherapy / Systemic Therapy

E. Reilly Scott, BS¹; Larry Harshyne, PhD²; Alban Linnenbach, PhD³; Elizaveta Flerova, MD⁴; Madalina Tuluc, MD⁴; Stacey Gargano, MD⁴; Sruti Tekumalla, BS¹; Derek Mann, BS³; Joseph Curry, MD³; David Cognetti, MD³; Athanassios Argiris, MD, PhD³; Andrew P South, PhD²; Jennifer M Johnson, MD⁴; Adam Luginbuhl, MD³

¹Sidney Kimmel Medical College, Thomas Jefferson University; ²Department of Dermatology and Cutaneous Biology, Thomas Jefferson University; ³Department of Otolaryngology - Head & Neck Surgery, Thomas Jefferson University; ⁴Department of Medical Oncology, Thomas Jefferson University

LYMPHOCYTES DERIVED FROM OPSCC-PATIENTS INDICATE AN HPV-DEPENDENT IMMUNE CHECKPOINT RECEPTOR PHENOTYPE DURING IN-VITRO HYPOMETHYLATING TREATMENT.

Immunotherapy / Systemic Therapy

Adrian Fehn; Ayla Grages; Adrian von Witzleben, Dr, med; Cornelia Brunner, Prof, Dr; Thomas K Hoffmann, Prof, Dr; Simon Laban, Prof, Dr

Ulm University Medical Center, Department of Oto-Rhino-Laryngology and Head & Neck Surgery

RANDOMIZED PHASE II MULTICENTER STUDY COMPARING MODIFIED PFE REGIMEN WITH MODIFIED TPEX REGIMEN IN RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK.

Immunotherapy / Systemic Therapy

Motoyuki Suzuki¹; Tadashi Sugasawa²; Hiroshi Hoshikawa³; Ayako Nakanome⁴; Takashi Fujii⁵; Mototsugu Shimokawa⁶; Hidenori Inohara¹

¹Department of Otorhinolaryngology Head and Neck Surgery, Osaka University Graduate School of Medicine; ²International Medical Center Head and Neck Oncology and Otorhinolaryngology, Saitama Medical University; ³Department of Otolaryngology - Head and Neck Surgery, Kagawa University School of Medicine; ⁴Department of Otolaryngology - Head and Neck Surgery, Tohoku University; ⁵Department of Head and Neck Surgery, Osaka International Cancer Institute; ⁶Department of Medical Statistics Yamaguchi University Graduate School of Medicine

ANTIGEN PROCESSING AND PRESENTATION REQUIRES STAT1, NLRC5, AND/OR P53 IN HEAD AND NECK CANCER CELLS

Immunotherapy / Systemic Therapy

Brendan L Kinney¹; Sreenivasulu Gunti²; Connor J Parrish¹; Vikash Kansal¹; Nicole C Schmitt¹

¹Emory University; ²NIDCD, NIH

IMMUNOTHERAPY FOR ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA: A FOCUS ON THE IMMUNOSUPPRESSED POPULATION

Immunotherapy / Systemic Therapy

Shahrukh Ali¹; Dan Yaniv, MD¹; Frederico O Gleber-Netto, DDS, MSc, PhD¹; Uma Ramesh¹; Elizabeth Chiang¹; Ryan P Goepfert, MD¹; Michael K Wong, MD, PhD¹; Renata Ferrarotto, MD¹; Frank E Mott, MD, FACP¹; Amy C Moreno, MD¹; David I Rosenthal, MD¹; Priyadharsini Nagarajan, MD, PhD, MBBS, FCAP, FASCP¹; Samantha Tam, MD²; Michael A Davies, MD, PhD¹; Michael R Migden, MD¹; Jeffrey N Myers, MD, PhD, FACS¹; Neil D Gross, MD, FACS¹; Moran Amit, MD, PhD¹

¹MD Anderson Cancer Center; ²Henry Ford Health System and Henry Ford Cancer Institute

PROGNOSTIC ROLE OF PRE-TREATMENT NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR) IN AN ASIAN COHORT OF PATIENTS WITH OROPHARYNGEAL SQUAMOUS CELL CARCINOMA

Oropharynx / HPV Related Disease

Isabelle J Jang¹; Hanis Binte Abdul Kadir¹; Daniel Chew²; Kok Hing Lim¹; Jacqueline S Hwang¹; Chwee Ming Lim¹

¹Singapore General Hospital; ²Singapore Health Services

PHASE II STUDY OF POST-OPERATIVE DURVALUMAB AND RADIOTHERAPY FOR INTERMEDIATE RISK HEAD AND NECK SQUAMOUS CELL CARCINOMA

Immunotherapy / Systemic Therapy

Siddharth H Sheth, DO, MPH¹; John Kaczmar, MD²; Allison Deal, MS¹; Shetal Patel, MD, PhD¹; Jeffrey Blumberg, MD¹; Trevor Hackman, MD¹; Samip Patel, MD¹; James Bonner, MD³; Bhisham Chera, MD²; Jared Weiss, MD¹

¹University of North Carolina; ²Medical University of South Carolina; ³University of Alabama - Birmingham

PRELIMINARY RESULTS OF THE PHASE 1 SURPASS TRIAL OF ADP-A2M4CD8, A NEXT-GENERATION SPEAR T-CELL THERAPY, IN PATIENTS WITH HEAD AND NECK CANCER

Immunotherapy / Systemic Therapy

David S Hong¹; Jon Zugazagoitia²; Mateo Bover²; Emiliano Calvo³; George R Blumenschein¹; Victor Moreno⁴; Quan Lin⁵; Thejo Annareddy⁵; Francine E Brophy⁶; Marisa Rosenberg⁶; Stavros Rafail⁶; Robert Harris⁶; Cheryl McAlpine⁶; Alex Tipping⁶; Jean-Marc Navenot⁶; Jose Saro⁶; Elliot Norry⁶; Marcus O Butler⁷

¹The University of Texas MD Anderson Cancer Center; ²Oncology Department, Hospital Universitario 12 de Octubre; ³Centro Integral Oncológico ClaraCampal, START Madrid-CIOCC; ⁴START Madrid-FJD, Fundación Jiménez Díaz Hospital; ⁵Adaptimmune (at the time of the study); ⁶Adaptimmune; ⁷Princess Margaret Cancer Centre

SPATIAL SIGNATURES IN TUMOR MICROENVIRONMENT REVEAL KEY FEATURES OF RESPONSE TO IMMUNOTHERAPY IN PATIENTS WITH HEAD AND NECK SQUAMOUS CELL CARCINOMA

Immunotherapy / Systemic Therapy

Daniel A Ruiz-Torres¹; Shun Hirayama¹; Joao P Oliveira, PhD²; Sara Cavallaro, PhD²; Evelyn Luciani²; Daniel L Faden, MD¹; Shannon L Stott, PhD²

¹Massachusetts Eye and Ear; ²Massachusetts General Hospital

PROTEIN TYROSINE KINASE 7 AND NEURAL/GLIAL ANTIGEN 2 EXPRESSION IN HEAD AND NECK SQUAMOUS CELL CARCINOMA PRIMARY TUMORS AND LYMPH NODE METASTASES: POTENTIAL TARGETS FOR ANTIBODY-DRUG CONJUGATE TREATMENT?

Immunotherapy / Systemic Therapy

Jeroen van Schaik, MD, PhD¹; Sjoukje Oosting, MD, PhD²; Bert van der Vegt, MD, PhD²; Rudolf Fehrmann, MD, PhD²; Boudewijn Plaat, MD, PhD²

¹University Hospital Basel, Basel, Switzerlandand and University Medical Center Groningen, Groningen, The Netherlands; ²University Medical Center Groningen, Groningen, The Netherlands